ScreenerHero
NWRNNewron Pharmaceuticals S.p.A.
SWX · CH · Healthcare · Biotechnology · newron.com
12.44CHF-1.11%Mkt Cap: 298.72M $P/E: —

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
ARGENX SE
$60.19BUSDP/E 39.1
UCB
UCB SA
$45.16BUSDP/E 19.2
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.17BUSDP/E 26.2
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5
ARWR
Arrowhead Pharmaceuticals, Inc.
$12.59BUSD

Key Statistics

Company
Market Cap298.72M $
Enterprise Value297.96M $
Revenue (TTM)21.83M $
Gross Profit21.83M $
Net Income (TTM)-15.11M $
Revenue/Share1.093 USD
Last Price12.44 CHF
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees27
CountryCH
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)16.88
PEG—
EV/EBITDA-55.83
EV/Revenue13.65
P/S13.68
P/B-24.06
EPS (TTM)-0.62
EPS (Forward)0.75
52W Range
12.3012% of range13.44
52W High13.44 CHF
52W Low12.30 CHF
Profitability
Gross Margin100.00%
Oper. Margin-83.59%
EBITDA Margin-24.45%
Profit Margin-69.22%
ROE118.90%
ROA-33.05%
Growth
Revenue Growth-84.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF36.92M $
CapEx (TTM)54.78K $
FCF Margin205.61%
FCF Yield15.02%
Net Debt10.60M $
Net Debt/EBITDA-1.99
Balance Sheet
Debt/Equity-3.43
Current Ratio0.76
Quick Ratio0.70
Book Value/Sh-0.5228 CHF
Cash/Share1.443 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)48.07 CHF
Upside (mean)+286.4%
Target Range35.68 CHF – 74.29 CHF
CHF35.68+286.4% to meanCHF74.29
# Analysts4
Ownership
Shares Out.20.81M
Float17.99M
Insiders13.11%
Institutions10.68%
Technical
SMA 5012.10 (+2.8%)
SMA 20016.48 (-24.5%)
Beta0.73
S&P 52W Chg18.16%
Avg Vol (30d)60.27K
Avg Vol (10d)53.77K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—